Log In
BCIQ
Print this Print this
 

verinurad (RDEA3170)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionNext-generation selective URAT1 transporter inhibitor
Molecular Target Solute carrier family 22 organic anion urate transporter member 12 (SLC22A12) (URAT1)
Mechanism of ActionUrate transporter 1 (URAT1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHyperuricemia / gout
Indication DetailsChronic management of hyperuricaemia in patients with gout; Treat gout
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,300.0M

$1,300.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/25/2012

$1,300.0M

$1,300.0M

0

Get a free BioCentury trial today